On August 30, 2007, the U.S. Food and Drug Administration (FDA) approved Somatuline Depot (lanreotide injection, developed by Tercica) for the treatment of acromegaly, a disorder in which there is overproduction of growth hormone. The FDA has approved Somatuline Depot for the long-term treatment of individuals with acromegaly who have not responded well to or can not be treated with surgery and/or radiation therapy.
- Learn more about acromegaly
- FDA press release about Somatuline Depot approval
Comments
Comments are closed for this post.
